<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="cough, and muscle ache [3,4], COVID-19 often enters the differential" exact="diagnosis" post="of dyspnea at rest and chest pain, which requires"/>
 <result pre="[22]. This estimates that each COVID-19 patient has been spreading" exact="infection" post="to 2.2 other people. Another important reason for the"/>
 <result pre="17.9% according to data from people who underwent a two-week" exact="quarantine" post="on the Diamond Princess cruise ship [24]. Unlike SARS-CoV,"/>
 <result pre="missed if the surveillance case definition only focuses on fever" exact="detection" post="[22]. The second most common symptom is cough (67.8%),"/>
 <result pre="disorders [29]. This may play a role as a clinical" exact="screening" post="tool to orientate testing of paucisymptomatic individuals, but larger"/>
 <result pre="play a role as a clinical screening tool to orientate" exact="testing" post="of paucisymptomatic individuals, but larger studies are warranted to"/>
 <result pre="show nonspecific ST-T abnormalities in some cases [30,31], but the" exact="prevalence" post="remains unknown. In laboratory tests, lymphocytopenia is commonly observed"/>
 <result pre="patients with severe ARDS who do not benefit from conventional" exact="treatment" post="might be successfully supported with venovenous extracorporeal membrane oxygenation"/>
 <result pre="retrospective case series including 144 patients with SARS examined the" exact="prevalence" post="of cardiac disease, DM, and cancer to be 8%,"/>
 <result pre="present in approximately 30% of the patients [41]. The higher" exact="prevalence" post="of CVD in MERS may be partly explained by"/>
 <result pre="A number of studies in the available literature illustrate the" exact="prevalence" post="of CVD in COVID-19 patients, which are described in"/>
 <result pre="COVID-19. An increased rate of adverse CVD events following COVID-19" exact="infection" post="might also play a role in prognosis, similar to"/>
 <result pre="high inflammatory burden of COVID-19, significant CV complications with COVID-19" exact="infection" post="are expected. Previous reports have suggested that COVID-19 leads"/>
 <result pre="SARS patients [53]. They confirmed their findings by inducing pulmonary" exact="infection" post="with human SARS-CoV in mice, which led to ACE2-dependent"/>
 <result pre="with human SARS-CoV in mice, which led to ACE2-dependent myocardial" exact="infection" post="in the heart. Likewise, an acute myocarditis in MERS"/>
 <result pre="that the heart can be directly involved in the viral" exact="infection" post="by SARS-CoV-2 [57]. Endocardial biopsy from a COVID-19 patient"/>
 <result pre="these findings suggest that an acute myocardial injury in SARS-CoV-2" exact="infection" post="may occur as the disease severity advance by cytokine"/>
 <result pre="severity advance by cytokine storms and systemic inflammation or viral" exact="infection" post="to the myocardium. Several COVID-19 cases were reported to"/>
 <result pre="underlying CVD and the evidence of myocardial injury for prioritized" exact="treatment" post="and even more aggressive treatment strategies. 5.2. Decompensated Heart"/>
 <result pre="of myocardial injury for prioritized treatment and even more aggressive" exact="treatment" post="strategies. 5.2. Decompensated Heart Failure and Mixed Shock The"/>
 <result pre="treatment strategies. 5.2. Decompensated Heart Failure and Mixed Shock The" exact="prevalence" post="of new-onset heart failure during COVID-19 associated hospitalization was"/>
 <result pre="Most recently, Fried et al. described three cases of COVID-19" exact="infection" post="with acute systolic heart failure [30], suggesting that isolated"/>
 <result pre="pulmonary infiltration), echocardiography and serum BNP may help clarify the" exact="diagnosis" post="[12]. In particular, COVID-19 infection can cause acute decompensated"/>
 <result pre="BNP may help clarify the diagnosis [12]. In particular, COVID-19" exact="infection" post="can cause acute decompensated heart failure when underlying cardiovascular"/>
 <result pre="personnel to provide complex therapeutic interventions while adhering to strict" exact="infection" post="control measures are all crucial components of an ECMO"/>
 <result pre="and arrhythmia in patients with COVID-19 [42]. In addition, high" exact="prevalence" post="of arrhythmia in patients with severe disease might be,"/>
 <result pre="or neurohormonal or inflammatory stress in the setting of viral" exact="infection" post="[12]. 5.4. Venous Thromboembolism Clotting and development of coagulopathy"/>
 <result pre="at initial presentation that ranges between 60% and 71% [76,77]," exact="screening" post="CT for the identification of COVID-19 has been extensively"/>
 <result pre="be observed in other cardiovascular complications. The only widely available" exact="treatment" post="for VTE is prophylactic dose low molecular heparin which"/>
 <result pre="be paid to the danger of VTE associated with COVID-19" exact="infection" post="in clinical practice. 5.5. COVID-19 and RAAS Inhibitors ACE2,"/>
 <result pre="Similar to SARS [102] and MERS [22], no specific drug" exact="treatment" post="exists for COVID-19 and supportive treatment is the mainstay"/>
 <result pre="[22], no specific drug treatment exists for COVID-19 and supportive" exact="treatment" post="is the mainstay of management. However, numerous studies are"/>
 <result pre="of hospitalization for pneumonia long after resolution of the index" exact="infection" post="[56]. Nevertheless, long-term follow-up data concerning the survivors of"/>
 <result pre="of observational studiesHeart (Br. Card. Soc.)202010635035710.1136/heartjnl-2019-31519331444266 48.CaldeiraD.RodriguesB.DavidC.CostaJ.PintoF.J.FerreiraJ.J.The association of influenza" exact="infection" post="and vaccine with myocardial infarction: Systematic review and meta-analysis"/>
 <result pre="al.Evaluating the accuracy of different respiratory specimens in the laboratory" exact="diagnosis" post="and monitoring the viral shedding of 2019-nCoV infectionsmedRxiv202010.1101/2020.02.11.20021493 78.AlosaimiB.HamedM.E.NaeemA.AlsharefA.A.AlQahtaniS.Y.AlDosariK.M.AlamriA.A.Al-EisaK.KhojahT.AssiriA.M.et"/>
 <result pre="and monitoring the viral shedding of 2019-nCoV infectionsmedRxiv202010.1101/2020.02.11.20021493 78.AlosaimiB.HamedM.E.NaeemA.AlsharefA.A.AlQahtaniS.Y.AlDosariK.M.AlamriA.A.Al-EisaK.KhojahT.AssiriA.M.et al.MERS-CoV" exact="infection" post="is associated with downregulation of genes encoding Th1 and"/>
 <result pre="changes in patients with viral pneumoniaEmerg. Microbes Infect.2020972773210.1080/22221751.2020.174619932196410 80.EscherR.BreakeyN.LÃ¤mmleB.Severe COVID-19" exact="infection" post="associated with endothelial activationThromb. Res.202010.1016/j.thromres.2020.04.014 81.SarduC.GambardellaJ.MorelliM.B.WangX.MarfellaR.SantulliG.Is COVID-19 an Endothelial"/>
 <result pre="COVID-19 an Endothelial Disease? Clinical and Basic EvidencePreprints202010.20944/preprints202004.0204.v1 82.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet (Lond. Engl.)202010.1016/S0140-6736(20)30937-5 83.SantosA.R.FreitasP.FerreiraJ.OliveiraA.GoncalvesM.FariaD.Bicho AugustoJ.SimoesJ.SantosA.GagoM.et al.Risk"/>
 <result pre="(2019-nCoV) in vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 105.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
</results>
